Bacillus clausii probiotic strains

antimicrobial and immunomodulatory activities.

Maria C. Urdaci, Philippe Bressollier, Iryna Pinchuk

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

The clinical benefits observed with probiotic use are mainly attributed to the antimicrobial substances produced by probiotic strains and to their immunomodulatory effects. Currently, the best-documented probiotic bacteria used in human therapy are lactic acid bacteria. In contrast, studies aiming to characterize the mechanisms responsible for the probiotic beneficial effects of Bacillus are rare. The current work seeks to contribute to such characterization by evaluating the antimicrobial and immunomodulatory activities of probiotic B. clausii strains. B. clausii strains release antimicrobial substances in the medium. Moreover, the release of these antimicrobial substances was observed during stationary growth phase and coincided with sporulation. These substances were active against Gram-positive bacteria, in particular against Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile. The antimicrobial activity was resistant to subtilisin, proteinase K, and chymotrypsin treatment, whereas it was sensitive to pronase treatment. The evaluation of the immunomodulatory properties of probiotic B. clausii strains was performed in vitro on Swiss and C57 Bl/6j murine cells. The authors demonstrate that these strains, in their vegetative forms, are able to induce NOS II synthetase activity, IFN-gamma production, and CD4 T-cell proliferation.

Original languageEnglish (US)
JournalJournal of Clinical Gastroenterology
Volume38
Issue number6 Suppl
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Probiotics
Bacteria
Subtilisin
Enterococcus faecium
Endopeptidase K
Pronase
Clostridium difficile
Chymotrypsin
Gram-Positive Bacteria
Nitric Oxide Synthase Type II
Human Milk
Ligases
Bacillus
Staphylococcus aureus
Bacillus clausii
Lactic Acid
Cell Proliferation
T-Lymphocytes
Growth

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Bacillus clausii probiotic strains : antimicrobial and immunomodulatory activities. / Urdaci, Maria C.; Bressollier, Philippe; Pinchuk, Iryna.

In: Journal of Clinical Gastroenterology, Vol. 38, No. 6 Suppl, 07.2004.

Research output: Contribution to journalArticle

Urdaci, Maria C. ; Bressollier, Philippe ; Pinchuk, Iryna. / Bacillus clausii probiotic strains : antimicrobial and immunomodulatory activities. In: Journal of Clinical Gastroenterology. 2004 ; Vol. 38, No. 6 Suppl.
@article{a3b7cb52836b4042abe5b78be5dfbbd5,
title = "Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities.",
abstract = "The clinical benefits observed with probiotic use are mainly attributed to the antimicrobial substances produced by probiotic strains and to their immunomodulatory effects. Currently, the best-documented probiotic bacteria used in human therapy are lactic acid bacteria. In contrast, studies aiming to characterize the mechanisms responsible for the probiotic beneficial effects of Bacillus are rare. The current work seeks to contribute to such characterization by evaluating the antimicrobial and immunomodulatory activities of probiotic B. clausii strains. B. clausii strains release antimicrobial substances in the medium. Moreover, the release of these antimicrobial substances was observed during stationary growth phase and coincided with sporulation. These substances were active against Gram-positive bacteria, in particular against Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile. The antimicrobial activity was resistant to subtilisin, proteinase K, and chymotrypsin treatment, whereas it was sensitive to pronase treatment. The evaluation of the immunomodulatory properties of probiotic B. clausii strains was performed in vitro on Swiss and C57 Bl/6j murine cells. The authors demonstrate that these strains, in their vegetative forms, are able to induce NOS II synthetase activity, IFN-gamma production, and CD4 T-cell proliferation.",
author = "Urdaci, {Maria C.} and Philippe Bressollier and Iryna Pinchuk",
year = "2004",
month = "7",
language = "English (US)",
volume = "38",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "6 Suppl",

}

TY - JOUR

T1 - Bacillus clausii probiotic strains

T2 - antimicrobial and immunomodulatory activities.

AU - Urdaci, Maria C.

AU - Bressollier, Philippe

AU - Pinchuk, Iryna

PY - 2004/7

Y1 - 2004/7

N2 - The clinical benefits observed with probiotic use are mainly attributed to the antimicrobial substances produced by probiotic strains and to their immunomodulatory effects. Currently, the best-documented probiotic bacteria used in human therapy are lactic acid bacteria. In contrast, studies aiming to characterize the mechanisms responsible for the probiotic beneficial effects of Bacillus are rare. The current work seeks to contribute to such characterization by evaluating the antimicrobial and immunomodulatory activities of probiotic B. clausii strains. B. clausii strains release antimicrobial substances in the medium. Moreover, the release of these antimicrobial substances was observed during stationary growth phase and coincided with sporulation. These substances were active against Gram-positive bacteria, in particular against Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile. The antimicrobial activity was resistant to subtilisin, proteinase K, and chymotrypsin treatment, whereas it was sensitive to pronase treatment. The evaluation of the immunomodulatory properties of probiotic B. clausii strains was performed in vitro on Swiss and C57 Bl/6j murine cells. The authors demonstrate that these strains, in their vegetative forms, are able to induce NOS II synthetase activity, IFN-gamma production, and CD4 T-cell proliferation.

AB - The clinical benefits observed with probiotic use are mainly attributed to the antimicrobial substances produced by probiotic strains and to their immunomodulatory effects. Currently, the best-documented probiotic bacteria used in human therapy are lactic acid bacteria. In contrast, studies aiming to characterize the mechanisms responsible for the probiotic beneficial effects of Bacillus are rare. The current work seeks to contribute to such characterization by evaluating the antimicrobial and immunomodulatory activities of probiotic B. clausii strains. B. clausii strains release antimicrobial substances in the medium. Moreover, the release of these antimicrobial substances was observed during stationary growth phase and coincided with sporulation. These substances were active against Gram-positive bacteria, in particular against Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile. The antimicrobial activity was resistant to subtilisin, proteinase K, and chymotrypsin treatment, whereas it was sensitive to pronase treatment. The evaluation of the immunomodulatory properties of probiotic B. clausii strains was performed in vitro on Swiss and C57 Bl/6j murine cells. The authors demonstrate that these strains, in their vegetative forms, are able to induce NOS II synthetase activity, IFN-gamma production, and CD4 T-cell proliferation.

UR - http://www.scopus.com/inward/record.url?scp=4844221595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4844221595&partnerID=8YFLogxK

M3 - Article

VL - 38

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 6 Suppl

ER -